Publications by Yugang Guo | EPFL Graph Search

The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer

Li Tang, Lucia Bonati, Mei-Wen Peng, Rongrong Li, Yugang Guo, Yang Zhao, Bing Feng

Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1 ...

2024

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Li Tang, Yugang Guo, Yang Zhao, Yuqing Xie, Bing Feng, Xiaomeng Hu

The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in ...

Nature Portfolio2024

Il-21 fusion proteins useful as enhancers of anti-cancer immunotherapies

Li Tang, Yugang Guo

The present invention relates generally to the field of anti-cancer therapy, in particular to the use of agents or co-agents useful in anti-cancer immunotherapy such as adoptive T-cell transfer (ACT) immunotherapy and immune check-point blockades. ...

2024

Highly effective adoptive t cell therapy

Li Tang, Yugang Guo, Bing Feng

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions ...

2023

Il-10 expressing cells for enhanced cancer immunotherapies

Li Tang, Yugang Guo, Yang Zhao

The present invention relates generally to the field of anti-cancer therapy, in particular to the use of adoptive T cell transfer therapy for treating cancer, in particular sold tumors. More specifically, the present invention relates to immune cells compr ...

2023

Il10/fc fusion proteins useful as enhancers of immunotherapies

Li Tang, Yugang Guo, Yuqing Xie

The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof. ...

2021

Switchable immune modulator for tumor-specific activation of anticancer immunity

Li Tang, Yugang Guo, Min Gao, Yu Zhao

Immune stimulatory antibodies and cytokines elicit potent antitumor immunity. However, the dose-limiting systemic toxicity greatly hinders their clinical applications. Here, we demonstrate a chemical approach, termed "switchable" immune modulator (Sw-IM), ...

2021

Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy

Georg Fantner, Mahmut Selman Sakar, Li Tang, Lucia Bonati, Murat Kaynak, Mélanie Thérèse Marie Hannebelle, Yugang Guo, Yuqing Xie, Min Gao, Armand Kurum

Cancer cells enriched in cholesterol in their plasma membrane impair T-cell-mediated cytotoxicity, which can be augmented by stiffening the cancer cells via cholesterol depletion, as shown in mouse models of adoptive T-cell immunotherapy. Malignant transfo ...

2021

Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity

Li Tang, Yugang Guo, Yang Zhao, Min Gao, Bing Feng

Tang and colleagues show that a half-life-extended IL-10-Fc fusion protein acts directly on terminally exhausted PD1(+)TIM-3(+)CD8(+) T cells to enhance their proliferation and effector function by reprogramming the cellular metabolism to oxidative phospho ...

2021

A Manganese Phosphate Nanocluster Activates the cGAS‐STING Pathway for Enhanced Cancer Immunotherapy

Li Tang, Yugang Guo, Yuqing Xie, Min Gao, Armand Kurum, Kewen Lei, Yu Zhao, Xiaomeng Hu, Simon Bart M. Van Herck

Targeting the stimulator of interferon genes (STING) pathway with cyclic dinucleotides (CDNs), the natural STING agonists, is a promising immunotherapeutic strategy for cancer. However, the clinical application of natural CDNs as therapeutics is greatly hi ...

2021